Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
11,049
Total Claims
$6.4M
Drug Cost
1,322
Beneficiaries
$4,868
Cost/Patient
Risk Score Breakdown 13/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+245%
Cost per patient vs peers
$4,868 vs $1,411 avg
+512%
Brand preference vs peers
65.1% vs 10.6% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
Brand vs Generic
Brand: 6,322 claims · $5.3M
Generic: 3,389 claims · $141K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 697 | $843K |
| Insulin Glargine/Lixisenatide | 621 | $683K |
| Insulin Pump Cart,automated,bt | 333 | $570K |
| Dulaglutide | 395 | $507K |
| Insulin Aspart | 308 | $320K |
| Empagliflozin | 261 | $280K |
| Insulin Pump Cart,cont Inf,bt | 157 | $259K |
| Semaglutide | 150 | $238K |
| Dapagliflozin Propanediol | 199 | $182K |
| Insulin Lispro | 143 | $167K |
| Sitagliptin Phos/Metformin Hcl | 198 | $162K |
| Tirzepatide | 118 | $147K |
| Insulin Aspart | 168 | $139K |
| Insulin Lispro Protamin/Lispro | 96 | $137K |
| Insulin Regular, Human | 40 | $94K |
Prescribing Profile
Patient Profile
74
Avg Age
66%
Female
2.16
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data